Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Value of Serum S-100B for Prediction of Distant Relapse and Survival in Stage III B/C Melanoma

L.H.M. SMIT, O.E. NIEWEG, W.J. MOOI, J.M.G. BONFRER, J.B.A.G. HAANEN, B.B.R. KROON and G.C. DE GAST
Anticancer Research July 2008, 28 (4C) 2297-2302;
L.H.M. SMIT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Leoniesmit@hotmail.com
O.E. NIEWEG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W.J. MOOI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.M.G. BONFRER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.B.A.G. HAANEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B.B.R. KROON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G.C. DE GAST
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: The biochemical marker serum S-100B has been proven to reflect the stage of melanoma and to be useful for disease monitoring and prediction of survival, mainly in stage IV disease. For stage III melanoma, limited data are available and its predictive value for relapse is unknown. Serum S-100B was evaluated prospectively for monitoring response and its predictive value for relapse and overall survival in stage IIIB/C melanoma patients. Patients and Methods: Treatment consisted of one cycle of neoadjuvant and adjuvant chemo(immuno)therapy, around surgery. S-100B was measured at enrollment and prior to and following surgery. The levels of S-100B in serum were compared to the pattern and intensity of the expression of S-100B in the melanoma tissue. Results: Some patients with normal initial S-100B values (n=18) showed responses (3 complete remission and 2 partial remission), in contrast to patients with elevated S-100B values. Distant relapse within one year was found in 11/23 (48%) patients with increased S-100B versus 2/18 (11%) patients with a normal value (p=0.01). Overall survival was decreased in patients with increased S-100B compared to those with normal S-100B (p=0.02). Correlations between the pattern and intensity of S-100B expression in the tumor specimen and the value of serum the S-100B did not reach statistical significance. Conclusion: Serum S-100B is a valuable biomarker for the evaluation of response to treatment and prediction of early distant relapse and survival in stage IIIB/C melanoma. The marginal correlation between serum S-100B values and expression of S-100B in the tumor specimens needs further study.

  • S-100B
  • melanoma
  • stage IIIB/C
  • relapse
  • survival
  • prediction

Footnotes

  • Received February 29, 2008.
  • Revision received May 27, 2008.
  • Accepted June 2, 2008.
  • Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 28 (4C)
Anticancer Research
Vol. 28, Issue 4C
July-August 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Value of Serum S-100B for Prediction of Distant Relapse and Survival in Stage III B/C Melanoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 11 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Value of Serum S-100B for Prediction of Distant Relapse and Survival in Stage III B/C Melanoma
L.H.M. SMIT, O.E. NIEWEG, W.J. MOOI, J.M.G. BONFRER, J.B.A.G. HAANEN, B.B.R. KROON, G.C. DE GAST
Anticancer Research Jul 2008, 28 (4C) 2297-2302;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Value of Serum S-100B for Prediction of Distant Relapse and Survival in Stage III B/C Melanoma
L.H.M. SMIT, O.E. NIEWEG, W.J. MOOI, J.M.G. BONFRER, J.B.A.G. HAANEN, B.B.R. KROON, G.C. DE GAST
Anticancer Research Jul 2008, 28 (4C) 2297-2302;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Serum S100B and LDH Are Not Useful in Predicting the Sentinel Node Status in Melanoma Patients
  • Google Scholar

More in this TOC Section

  • Comparison of BRCA2 Single Nucleotide Variants Between Japanese Patients With Familial Prostate Cancer, Sporadic Prostate Cancer, and Benign Prostatic Hyperplasia
  • Corrigendum
  • Sex-related Survival Differences in Patients With Glioblastoma – Results From a Retrospective Analysis
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire